Literature DB >> 15814667

Itk is not essential for CD28 signaling in naive T cells.

Cheng-Rui Li1, Leslie J Berg.   

Abstract

Itk, a member of the Tec family of tyrosine kinases, is critical for TCR signaling, leading to the activation of phospholipase C gamma1. Early biochemical studies performed in tumor cell lines also implicated Itk in CD28 signaling. These data were complemented by functional studies on primary Itk-/- T cells that suggested a negative role for Itk in CD28 signaling. In this report, we describe a thorough analysis of CD28-mediated responses in T cells lacking Itk. Using purified naive CD4+ T cells from Itk-/- mice, we examine a range of responses dependent on CD28 costimulation. We also analyze Akt and glycogen synthase kinase-3beta phosphorylation in response to stimulation of CD28 alone. Overall, these experiments demonstrate that CD28 signaling, as well as CD28-mediated costimulation of TCR signaling, function efficiently in the absence of Itk. These findings indicate that Itk is not essential for CD28 signaling in primary naive CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814667     DOI: 10.4049/jimmunol.174.8.4475

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Quantitative analysis of T cell homeostatic proliferation.

Authors:  Cheng-Rui Li; Sharon Santoso; David D Lo
Journal:  Cell Immunol       Date:  2008-03-03       Impact factor: 4.868

2.  Naive and innate memory phenotype CD4+ T cells have different requirements for active Itk for their development.

Authors:  Jianfang Hu; Avery August
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling.

Authors:  Jonathan A Deane; Michael G Kharas; Jean S Oak; Linda N Stiles; Ji Luo; Travis I Moore; Hong Ji; Christian Rommel; Lewis C Cantley; Thomas E Lane; David A Fruman
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

4.  SILAC Phosphoproteomics Reveals Unique Signaling Circuits in CAR-T Cells and the Inhibition of B Cell-Activating Phosphorylation in Target Cells.

Authors:  Alijah A Griffith; Kenneth P Callahan; Nathan Gordo King; Qian Xiao; Xiaolei Su; Arthur R Salomon
Journal:  J Proteome Res       Date:  2022-01-11       Impact factor: 4.466

Review 5.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

6.  Antigenic experience dictates functional role of glycogen synthase kinase-3 in human CD4+ T cell responses.

Authors:  Carlos A Garcia; Manjunatha R Benakanakere; Pascale Alard; Michelle M Kosiewicz; Denis F Kinane; Michael Martin
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

7.  Selective targeting of ITK blocks multiple steps of HIV replication.

Authors:  Julie A Readinger; Gillian M Schiralli; Jian-Kang Jiang; Craig J Thomas; Avery August; Andrew J Henderson; Pamela L Schwartzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

Review 8.  ITK inhibitors in inflammation and immune-mediated disorders.

Authors:  Nisebita Sahu; Avery August
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

9.  Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.

Authors:  John D Harling; Angela M Deakin; Sébastien Campos; Rachel Grimley; Laiq Chaudry; Catherine Nye; Oxana Polyakova; Christina M Bessant; Nick Barton; Don Somers; John Barrett; Rebecca H Graves; Laura Hanns; William J Kerr; Roberto Solari
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

10.  PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors.

Authors:  Noah Isakov; Amnon Altman
Journal:  Front Immunol       Date:  2012-08-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.